![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Introduction: Pilot studies of bortezomib in combination therapy for relapsed B and T acute lymphoblastic leukemia (ALL) showed encouraging activity compared with registry data of previous and current aggressive re-induction regimens. There has been no increased toxicity with the addition of bortezomib in these trials. There are currently phase III multi-agent chemotherapy trials randomizing bortezomib vs. none in children with newly diagnosed T-ALL and relapsed B-ALL.
Areas covered: This paper reviews the history of bortezomib to its current status in randomized clinical trials. Bortezomib is very active in multiple myeloma and would be predicted to be active in ALL based on the high concordance of single agent chemotherapy activity in these diseases. Potential toxicity unique to children will be presented.
Expert opinion: Bortezomib in combination therapy has shown encouraging activity in every relapsed ALL study to date. The results of ongoing trials should lead to additional trials optimizing its use in combination therapy for newly diagnosed and relapsed ALL.
Acknowledgment
The author thanks Yoav Messinger for critically reviewing this manuscript.
Declaration of interests
The author has no relevant affiliations or financial involvement with any organization of entity with a financial interest in or financial conflict with the subject matter of materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents, received of pending or royalties.